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ABSTRACT A mass spectrometry (MS) method that detects a serum disaccharide
(DS) (MS-DS) was recently described for the diagnosis of invasive fungal infec-
tions (IFI). We carried out a European collaborative study to evaluate this assay.
Patients with the following IFI were selected according to the availability of sera
obtained at about the time that IFI was documented: invasive candidiasis (IC;
n 26 patients), invasive aspergillosis (IA; n 19), and mucormycosis (MM;
n 23). Control sera originated from 20 neutropenic patients and 20 patients
with bacteremia. MS-DS was carried out in blind manner for the diagnosis of IFI.
A diagnosis of IC or IA was conﬁrmed by detection of mannan (Man) or galacto-
mannan (GM), respectively, associated with detection of (1,3)--D-glucan (BDG) in
both infections. MM was detected by quantitative real-time PCR (qPCR). All tests
discriminated sera from patients with IC from sera from control subjects with
bacteremia (P 0.0009). For IC, the MS-DS sensitivity and speciﬁcity were 51%
and 87%, respectively. MS-DS complemented the high speciﬁcity of Man moni-
toring. All tests discriminated sera from IA patients from sera from neutropenic
controls (P 0.0009). For IA, MS-DS sensitivity and speciﬁcity were 64% and 95%,
respectively. Only 13/36 serum samples from patients with MM were concordant
by MS-DS and qPCR (6 were positive, and 7 were negative); 14 were positive by
MS-DS alone. qPCR and MS-DS made a similar contribution to the diagnosis of
MM. In patients undergoing long-term monitoring, the persistent circulation of
serum disaccharide was observed, whereas DNA was detected only for a short
period after initiation of treatment. MS-DS has an important role to play in the
early diagnosis of IFI. Its panfungal nature and complementarity with other tests
may justify its use in the management of IFI.
KEYWORDS invasive aspergillosis, invasive candidiasis, invasive fungal infection,
mass spectrometry, mucormycosis, serological diagnosis
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Numerous reports have described the increasing problem of nosocomial invasivefungal infections (IFI) in immunocompromised patients (1, 2). This is due to the
increased number of at-risk patients in parallel with progress in intensive care and/or
hematology, leading to deeper or longer immunosuppression (3). In parallel, the
spectrum of isolated fungi has shifted from well-known opportunistic pathogens with
characterized virulence factors (4, 5) to other species rarely reported to be a cause of
human infection (6–8). Disruptions in the microbial balance induced by antibacterial
antibiotics favor fungal ﬁtness (9). Antifungal therapy is generally prescribed in patients
with persistent fever despite 3 days of antibiotic treatment (10). Diagnostic strategies
involve conventional methods of isolation and identiﬁcation of fungi from blood or
sterile sites, imaging, and a panel of biological tests whose nature depends on the
fungal agent suspected (11, 12). The few biological tests currently considered by
physicians to be of diagnostic help do not involve changes in the host response related
to fungal infections (e.g., antifungal antibodies [13] or cytokine proﬁling [14]) but
consist of the detection of circulating fungal molecules, either glycans or DNA, in the
patients’ sera using tests developed with the advent of hybridoma technology (15, 16),
discoveries in biochemical cascades (17), or PCR (18). Due to the poor sensitivity of
conventional mycological methods (12, 19), infectious disease societies have produced
different levels of recommendations for immunological tests for the diagnosis of
invasive candidiasis (IC) and invasive aspergillosis (IA) (20, 21). These tests, which are
considered speciﬁc but which sometimes lack sensitivity, were later complemented by
recommendations for the more sensitive Fungitell test, which detects both IC and IA
(22). Despite years of extensive research into the detection of fungal DNA, a consensus
has been reached only for IA, while standardization is still in progress for IC and
mucormycosis (MM) (23). For MM, a standardized PCR method would be of primary
interest since, in contrast to IC, glycan detection tests are not available (24). Recently,
the T2MR technology, combining DNA ampliﬁcation and detection by magnetic reso-
nance, has provided signiﬁcant progress in terms of reducing the delay in the time to
diagnosis in comparison with the time to diagnosis by blood cultures for IC (25). More
recently, matrix-assisted laser desorption ionization–time of ﬂight (MALDI-TOF) mass
spectrometry (MS) has become essential in clinical mycology laboratories, providing a
more rapid and accurate means of identiﬁcation of fungal species isolated from
patients (26).
We developed an approach based on the ability of MS to detect fungal molecules
in patients’ sera (27). Subsequent work showed that this method, which allows the
detection and relative quantiﬁcation of a panfungal serum disaccharide (DS), gave
results that were comparable to those of methods recommended for the diagnosis of
IFI (28). Here, we describe the results of a European collaborative study carried out in
a blind manner to validate the use of MS for DS (MS-DS) for the diagnosis of IFI.
(This study was presented in part at the Russian Scientiﬁc Conference on Medical
Microbiology and Clinical Mycology, Saint Petersburg, Russia, 14 to 16 June 2016; at the
13th Annual Fungal Update meeting, St Bartholomew’s Hospital, London, United
Kingdom, 2 to 3 March 2018; and as an e-poster at the 20th Congress of the Interna-
tional Society for Human and Animal Mycology, Amsterdam, Netherlands, 30 June to 4
July 2018 [29].)
MATERIALS AND METHODS
Study design and participants. Different centers provided sera from patients with IFI classiﬁed as
proven or probable according to the European Organization for the Research and Treatment of Cancer
(EORTC)/Mycoses Study Group (MSG) criteria (30). Patients with IC were selected at the University
Hospital of Genoa and Catholic University of Sacred Heart, Rome, Italy. Controls for IC patients consisted
of febrile patients who were admitted to the Emergency Department of the University Hospital of
Lausanne, Lausanne, Switzerland, and in whom bacteremia was subsequently documented. Two cases of
nocardiosis from Lille University Hospital were also included among the controls. Patients with IA were
selected at the University Hospital of Strasbourg, Strasbourg, France. Controls consisted of neutropenic
patients hospitalized at the University Hospital of Genoa. Patients with MM were selected at Saint Louis
University Hospital, Paris, France, and Lille University Hospital, Lille, France.
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Altogether 95 patients and 189 serum and plasma samples were selected. They were distributed as
follows: 17 patients with IC (27 serum samples), 19 patients with IA (53 serum samples), 16 patients with
MM (36 serum samples), 10 control neutropenic patients (20 serum samples), 20 patients (21 plasma
samples) with bacterial infections, and 2 patients with Actinomycete infections (2 serum samples).
MS-DS detection. Serum and plasma samples were frozen and sent on dry ice to the Laboratory of
Clinical Mycology, Lille University Hospital, for processing as described previously (27). After a preana-
lytical step for the extraction and puriﬁcation of oligosaccharides, spectra were recorded and analyzed
using a 4800 MALDI-TOF/TOF analyzer (Applied Biosystems/MDS Sciex) at a ﬁxed laser intensity within
a 300- to 800-m/z range (UMR CNRS 8576, University of Lille).
Detection of circulating poly- and oligosaccharides and DNA in serum or plasma. For the
diagnosis of IC and IA, detection of mannan (Man) or galactomannan (GM) and (1,3)--D-glucan (BDG)
was performed in the participating centers during routine patient screening or in the Lille Clinical
Mycology Laboratory if they had not been tested previously.
BDG was measured using a Fungitell kit (Associates of Cape Cod Inc., Falmouth, MA, USA) following
the manufacturer’s instructions. The recommended cutoff of 80 pg/ml was used to determine clinical
relevance.
Measurement of serum Man and GM was performed using a Platelia Candida Ag Plus test and Platelia
Aspergillus Ag test (Bio-Rad, Marnes la Coquette, France), respectively, according to the manufacturer’s
instructions. The recommended cutoffs of a concentration of 62.5 pg/ml and an index of 0.5, respec-
tively, were used.
For the diagnosis of MM, quantitative real-time PCR (qPCR) was performed as described previously
(24, 31).
Ethics statement. No additional sampling was necessary in any center due to the retrospective
nature of the study. In Lille, agreement for the establishment of a biological collection of IFI samples was
obtained from the French Ministry of Education and Research under reference number DC2008-642.
Institutional review board approval was granted by the Comité de Protection des Personnes Nord-Ouest
IV, the ethical committee of the university hospital of Lille.
Statistical analysis. GraphPad Prism (version 6) software was used to compare the distribution of
biomarkers in the different groups with the Mann-Whitney two-tailed test and to generate receiver
operating characteristic (ROC) curves, derive cutoffs, and construct graphs. A P value of 0.05 was
considered statistically signiﬁcant.
RESULTS
Invasive candidiasis. (i) Study population. The origin of the IC patients, the delay
to serum sampling in relation to the time of the ﬁrst positive blood culture, and the
Candida species isolated are shown in Table 1. The Candida species were representative
of the usual epidemiology encountered in southern Europe, with a higher prevalence
of Candida parapsilosis complex isolates. The control patients with bacteremia are listed
in Table 2. These included the usual panel of patients with community-acquired
bacterial infections and two cases of Nocardia infection.
(ii) MS-DS diagnosis of IC in comparison to BDG and Man detection. The
distribution of BDG and Man concentrations and MS-DS index values is shown in Fig.
1. All tests signiﬁcantly discriminated IC patients from bacteremic controls (P 0.0001).
Among the 27 IC patients, 9 were positive by all three tests, 12 were positive by two
tests (6 by BDG detection and MS-DS; 5 by BDG and Man detection; 1 by Man detection
and MS-DS), and 4 were positive by BDG detection alone. Only two patients (patients
I19 and I27) infected by C. parapsilosis and C. krusei were negative by all tests. When
considering control patients with bacteremia, three were positive by MS-DS, whereas
six were positive for BDG, including the patient with Nocardia infection who displayed
very high glucan levels. Only one control (patient S5) was positive for two biomarkers
(BDG and DS).
Figure 2 shows the ROC curves and corresponding sensitivities and speciﬁcities for
the MS-DS, BDG, and Man detection tests. When considering the results for serum
samples (Fig. 2A and B), application of the cutoff value of 325 for MS-DS showed a
sensitivity of 51% and a speciﬁcity of 87%, which were intermediate values compared
to those obtained by the BDG and Man tests. Analysis of the MS-DS index values for IC
diagnosis was then performed for patients (Fig. 2C and D), and the sensitivity reached
67% without altering the high speciﬁcity estimated for serum. Comparison of ROC
curves established for the MS-DS and the BDG and Man tests revealed that the
diagnostic value of MS-DS was similar to that of the BDG test and positively comple-
mented the high speciﬁcity of Man monitoring (revealed by the asymptotic curve). A
lack of concordance between MS-DS and the BDG and Man tests was observed for serial
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serum samples from a given patient. This appeared to be more moderate when
considering the global biomarker patterns per patient, since most patients (22/26)
aggregated into two groups: those that displayed three positive test and those that
displayed two positive tests. Figure 3A shows an example of biomarker kinetics during
TABLE 1 Origin of sera from patients with IC, delay between serum sampling and time of ﬁrst positive blood culture, and Candida
species isolateda
Patient no. (site) Species isolated Delay vs BC (days) Man concn (pg/ml) BDG concn (pg/ml) MS-DS index
I1 (G) Candida albicans 2 >500 688 2,000
C. albicans 5 >500 1,528 550
C. albicans 7 >500 861 625
I2 (G) C. albicans 2 81 943 79
C. albicans 5 192 405 133
C. albicans 7 79 286 200
I3 (G) C. albicans 2 69 155 400
C. albicans 7 30 108 526
C. albicans 13 12 50 300
I4 (G) C. albicans 0 >500 5,000 1,000
C. albicans 5 >500 5,000 333
C. albicans 7 >500 5,000 285
I5 (G) C. albicans 1 441 407 133
C. albicans 6 22 222 110
C. albicans 10 38 336 300
I6 (G) C. albicans 5 108 403 70
C. albicans 0 150 283 85
C. albicans 4 232 2,528 500
I7 (G) C. albicans 2 >500 850 350
C. albicans 10 >500 367 667
I8 (G) C. albicans 1 41 158 238
C. albicans 7 39 58 151
I9 (R) C. albicans 1 4 >500 1,000
I10 (R) C. albicans 2 0 >500 385
I11 (R) C. albicans 1 3 >500 175
C. albicans 0 3 >500 435
I12 (R) C. albicans 1 >500 >500 159
I13 (R) C. albicans 1 0 >500 122
I14 (R) C. glabrata 0 64 >500 78
I15 (G) C. tropicalis 3 >500 159 110
C. tropicalis 7 18 189 357
C. tropicalis 14 31 42 345
I16 (R) C. tropicalis 3 500 500 714
I17 (G) C. parapsilosis 2 5 61 53
C. parapsilosis 5 0 245 172
C. parapsilosis 6 82 7 238
I18 (G) C. parapsilosis 1 16 125 122
C. parapsilosis 4 14 159 400
C. parapsilosis 14 34 70 667
I19 (G) C. parapsilosis 0 21 26 159
C. parapsilosis 4 18 77 65
I20 (G) C. parapsilosis 1 110 39 833
C. parapsilosis 3 6 20 450
I21 (R) C. parapsilosis 1 2 >500 1,000
I22 (R) C. parapsilosis 1 NA >500 109
C. parapsilosis 1 NA >500 106
I23 (R) C. parapsilosis 7 256 >500 333
I24 (R) C. parapsilosis 0 0 >500 96
I25 (R) C. orthopsilosis 1 >500 >500 769
C. orthopsilosis 1 >500 >500 588
C. orthopsilosis 1 >500 >500 1,000
C. orthopsilosis 1 >500 >500 625
I26 (G) C. krusei 3 12 327 357
C. krusei 7 10 385 344
C. krusei 10 8 191 400
I27 (G) C. krusei 2 12 7 300
C. krusei 4 16 14 167
aBC, time of ﬁrst positive blood culture; BDG, (1,3)--D-glucan; G, Genoa, Italy; Man, mannan; MS-DS, mass spectrometry method for detection of a serum disaccharide;
NA, not available; R, Rome, Italy. Bold characters correspond to positive values.
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the time course of IC in one patient. Tests for BDG and Man were positive on day 1 and
decreased on day 7, whereas MS-DS became positive at the end of monitoring. Due to
the retrospective nature of the study, few serum samples were available per patient,
but analysis of the whole IC patient population conﬁrmed the transient nature of Man
detection, in contrast to a slower decrease in glucanemia.
Invasive aspergillosis. (i) Study population. The characteristics of the IA patients,
the level of certainty of a diagnosis of IA according to EORTC criteria, and the Aspergillus
species isolated are shown in Table 3. Except for one patient with invasive sinusitis, all
patients presented with invasive pulmonary aspergillosis. “Day 0” indicates the date of
the ﬁrst serum available in the collection relative to the episodes of IA deﬁned
according to clinical and radiological arguments.
The characteristics of the controls, consisting of neutropenic patients, are summa-
rized in Table 4. Retrospective analysis of the clinical evolution of IA revealed that
FIG 1 Distribution of MS-DS indexes (A), Man concentrations (B), and BDG concentrations (C) in patients with invasive
candidiasis (IC) versus the controls. The results for each biomarker for the patient and control groups were compared using
the Mann-Whitney test (signiﬁcant at P 0.05). The dotted lines represent the cutoff values for each biomarker.
FIG 2 (A, C) ROC curves for serum (A) and patients (C) for invasive candidiasis. Gray, dashed, and black lines, results for BDG
detection, Man detection, and MS-DS, respectively. (B, D) Sensitivity/speciﬁcity values according to preestablished cutoff
values for each biomarker for analysis of serum (B) and patients (D). AUC, area under the concentration-time curve.
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control patients 3, 6, and 7 developed probable IA 1, 2, and 6 months after serum
sampling, respectively.
(ii) MS-DS diagnosis of IA in comparison to BDG and GM detection. The
distribution of BDG concentrations and MS-DS index values is shown in Fig. 4. The
values for the biomarkers were signiﬁcantly higher in IA patients than in the controls
(P 0.0001).
The sensitivity, speciﬁcity, and cutoff values for MS-DS and BDG detection were
assessed by establishing ROC curves for serum, as shown in Fig. 5A and B. With a cutoff
value of 325 for the MS-DS index, the sensitivity and speciﬁcity were 64% and 95%,
respectively. The sensitivity values were intermediate between those for GM and BDG
detection, which had 100% speciﬁcity. Interestingly, the 95% speciﬁcity of MS-DS was
due to the high MS-DS index observed for control patient 6, who subsequently
developed IA. In Fig. 5C and D, an analysis of MS-DS index values for IA diagnosis was
performed for the patients, and no difference in terms of sensitivity and speciﬁcity was
revealed with the data obtained for serum. A comparison of MS-DS and BDG detection
ROC curves (according to the manufacturer’s recommended threshold) showed that
the diagnostic value of MS-DS was better than that of BDG detection, with a maximum
sensitivity of 64% for MS-DS and 50% for BDG detection.
Figure 3B shows an example of MS-DS and BDG detection kinetic evolution during
GM monitoring. For this patient, only one serum sample was positive at the GM cutoff
14 days after the beginning of monitoring, while BDG levels were already positive on
day 0, before increasing at unusually high levels. MS-DS was constantly positive during
the whole survey, although it decreased at the time when BDG levels and GM index
values were maximum.
Mucormycosis. (i) Study population. The characteristics of patients and the level
of certainty of a diagnosis of MM according to EORTC criteria are shown in Table 5. The
genera/species involved were representative of the usual spectra of Mucorales isolated,
as were the risk factors, infection sites, and high mortality.
(ii) MS-DS in comparison with qPCR for diagnosis of MM. In contrast to IC and IA,
no biochemical or immunological assays for the detection of circulating fungal poly- or
oligosaccharides are available for the diagnosis of MM. We therefore compared MS-DS
with qPCR, which is the only test currently available for the diagnosis of MM. The qPCR
method used detects species from the genera Mucor, Rhizomucor, Lichtheimia, and
Rhizopus.
We tested 36 serum samples from 16 patients (1 to 13 serum samples/patient) by
MS-DS and qPCR. The results for only 13 serum samples were concordant by both
methods (positive or negative). Among the 23 serum samples with discordant results,
13 were positive by MS-DS only and 10 were positive by qPCR only. Only three patients
FIG 3 Examples of kinetics of serum biomarkers in patients with invasive candidiasis (IC) (A), invasive aspergillosis (IA) (B),
and mucormycosis (MM) (C). Day 0 indicates the date of a positive fungal blood culture (BC) for IC or the ﬁrst available
serum sample for IA and the date of mycological evidence for MM. (A, B) Black circles and black solid line, MS-DS; black
triangles and dashed line, Man or GM detection; black squares and gray line, BDG detection. Biomarker levels are indicated
on the y axis with reference to BDG values (pg/ml), MS-DS index, and GM (index  1,000). (C) Empty and full circles,
negative and positive Mucorales qPCR results, respectively, for MM patients. Horizontal dotted lines indicate the cutoff
values for BDG (80 pg/ml), Man (62.5 pg/ml), GM (index value, 0.5 · 1,000), and MS-DS (index value, 325). d, day.
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were positive by both tests. Remarkably, all the patients in this series could be
diagnosed with MM by at least one test.
The distribution of MS-DS index values in relation to the date of IFI diagnosis and in
comparison to the qPCR results is shown in Fig. 6. Among the serum samples tested
before a mycological diagnosis was obtained, three (from three patients) were positive
by MS-DS and six (from ﬁve patients) were positive by qPCR. An example of the kinetic
evolution of MS-DS and qPCR in a patient from whom numerous samples were
available is shown in Fig. 3C. A steady increase in MS-DS index values was observed
during the 2 months of follow-up, whereas DNA circulation could be detected only
between day 0 and day 20.
DISCUSSION
In contrast to diagnostic tests for obligate pathogens, whose detection is indicative of
disease, diagnostic tests for opportunistic pathogens have to discriminate between the
TABLE 4 Origin of control sera used in MS-DS test for invasive aspergillosisa
Patient
no.
Age
(yr) Sex
Underlying
condition(s)
Antifungal
prophylaxis
Delay between serum
sample collections (days)
BDG concn
(pg/ml)
GM index
in serum
MS-DS
index
1 50 M Neutropenia, myeloﬁbrosis Fluconazole 0 7 0.07 68
3 7 0.08 86
2 40 M Neutropenia, Hodgkin’s disease Fluconazole 0 7 0.09 147
4 7 0.06 143
3 48 F Neutropenia, Allo-HSCT (ALL) No 0 7 0.18 200
5 7 0.21 81
4 44 F Neutropenia/GVHD, Allo-HSCT (myeloﬁbrosis) Posaconazole 0 7 0.04 161
1 7 0.04 120
5 21 F Neutropenia, Allo-HSCT (AML) Posaconazole 0 7 0.05 66
7 7 0.05 39
6 49 M Neutropenia, Allo-HSCT (myeloma) Fluconazole 0 7 0.10 400
3 7 0.06 200
7 57 F Neutropenia/GVHD, Allo-HSCT (AML) Fluconazole 0 7 0.03 200
7 7 0.04 300
8 75 F Neutropenia, AML Fluconazole 0 41 0.03 85
3 7 0.03 49
9 36 M Neutropenia, AML Posaconazole 0 7 0.05 58
3 7 0.03 86
10 52 F Neutropenia, AML Posaconazole 0 7 0.05 50
11 7 0.05 51
aALL, acute lymphoblastic leukemia; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; BDG, (1,3)--D-glucan; F, female; GM,
galactomannan; GVHD, graft-versus-host disease; M, male; MS-DS, mass spectrometry method for detection of a serum disaccharide. Bold characters correspond to
positive values.
FIG 4 Distribution of MS-DS indexes (A), GM indexes (B), and BDG concentrations (C) in patients with invasive aspergillosis
(IA) and controls. The patient and control groups were compared using the Mann-Whitney test (signiﬁcant at P 0.05). The
dotted lines represent the cutoff values for each biomarker.
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presence of microbes as endo- or exosaprophytes and their shift to a pathogen (19). This
is a kinetic process where the assay has to present the best compromise between speciﬁcity
and sensitivity over time from disease onset and its evolution to invasive infection.
Currently, for IC and IA, only two types of tests have been shown to be clinically useful for
disease management (6, 21, 32, 33). On the one hand, the Platelia Candida Ag Plus test and
Platelia Aspergillus Ag test, which detect Man and GM, respectively, are considered speciﬁc
but have a low sensitivity (especially for the detection of Man). On the other hand, the
Fungitell test, which detects BDG, is considered more sensitive but less speciﬁc. The results
of our previous study concerning MS-DS and those of the current study are in agree-
ment with these conclusions. In both studies, MS-DS appeared to provide interme-
diate results, being more sensitive than the Platelia tests but more speciﬁc than the
test for BDG (28). It is therefore suggested that MS-DS could be useful in the
management of patients at risk of IC and IA.
For some other IFI, such as those caused by Mucorales, the lack of glucans in their
cell wall and negativity for BDG in the context of host invasion have led to considerable
efforts to develop alternative diagnostic methods; a speciﬁc PCR is now available (24).
qPCR is of great help in the diagnosis of MM, whose emergence is worrying in terms
of incidence and severity (34). MS-DS was previously shown to be positive during MM
(28). In the present study, a comparison of the results of MS-DS with the results of qPCR
showed a similar performance, conﬁrming that a panfungal diagnostic assay is useful in
daily practice when an IFI is suspected without mycological evidence. The reproduc-
ibility of the sensitivity values in mono- and multicenter studies conﬁrms the robust
character of the Platelia and BDG tests, in line with their extensive use worldwide for
several decades. A similar reproducibility and, thus, robustness were observed for
MS-DS. Additional information regarding MS-DS speciﬁcity concerned the absence of
false positivity associated with Nocardia infection, in contrast to BDG detection, as
reported previously (35) and as recently observed for one of the two patients included
in this study. Conversely, among the three neutropenic patients who were included as
IA controls and who were revealed to have subsequently developed IA, none were
positive for either GM or BDG, while MS-DS index values were positive and above the
limit of signiﬁcance in two patients. Although these results could be considered a
coincidence, the long delay before disease development should be considered with
FIG 5 (A, C) ROC curves for serum (A) and patients (C) for invasive aspergillosis (IA). (B, D) Sensitivity/speciﬁcity values
according to preestablished cutoff values for each biomarker for analysis of serum (B) and patients (D). MS-DS*, results
obtained by exclusion of the control who developed IA 2 months later. Gray, dashed, and black lines, results for BDG
detection, GM detection, and MS-DS, respectively.
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caution due to the possible subclinical character of DS circulation. Unpublished data
described the structure and function of DS and showed that among the m/z 365
hex-disaccharide signals (27) is trehalose, an important fungal metabolite (36). What the
present study, investigating four different IFI biomarkers in comparison with DS, makes
particularly obvious is the different kinetics of their circulation, as shown in Fig. 3. From
a pathophysiological point of view, the metabolite DS has kinetics of synthesis and
release from fungal cells different from those of cell surface-associated Man and GM or
BDG, which is thought to be deeply anchored in the cell wall. These fungal polysac-
charides are synthesized in situ, and then different processes of degradation take place
as a result of either fungal or host carbohydrate catabolism. In parallel, binding to host
receptors, catabolism by host soluble enzymes, and circulation as immune complexes
make the levels in the circulation completely different. The efﬁciency of human
mannosidases, naturally present for degrading human glycoproteins, and the large
amount of antimannan antibodies present in IC patients are responsible for the rapid
clearance of mannan. In contrast, mammals are poorly equipped for degrading glucans,
which are not self-components, and their poor immunogenicity does not help with
TABLE 5 Origin of the sera used in the MS-DS test for detection of mucormycosisa
Patient
no. (site)
Age
(yr) Sex
Underlying
condition(s) Site(s) of MM Imaging result
Diagnostic
sample
Histology/
DE Species
1 (P) 27 M Lymphoma Lung Bronchiectasis, ground
glass
Sputum NA Syncephalastrum sp. culture
2 (P) 23 F AML Lung Nodule Biopsy Hyphae Lichtheimia corymbifera PCR
3 (P) 18 F ALL Liver Nodule Biopsy Hyphae Mucor sp. culture
4 (P) 75 M Myelodysplasia Rhinocerebral Sinus, eye, and brain
invasion
Conjunctival
swab
Hyphae Lichtheimia sp. culture
5 (P) 72 M AML Lung Nodule Serum NA Rhizomucor sp. PCR
6 (P) 77 F ALL Lung Nodule Serum NA Mucor sp. PCR
7 (P) 19 F Aplastic Fanconi
anemia
Lung and kidney Nodule Kidney biopsy Hyphae Rhizomucor sp. PCR
8 (P) 57 M AML Liver Nodule Biopsy Hyphae Lichtheimia sp. culture
9 (L) 61 F Allo-HSCT Lung Nodule Biopsy Hyphae Rhizopus microsporus culture
10 (L) 66 F Burns, CML Skin NA Swab Neg Lichtheimia ramosa culture
11 (L) 45 F Allo-HSCT GVHD Postoperative abscess,
abdominal wall (biopsy)
NA Biopsy Hyphae Rhizopus arrhizus culture
12 (L) 42 M Burns Skin NA Biopsy Hyphae L. corymbifera culture
13 (L) 83 F Lymphoma, rituximab,
diabetes
Lung Nodule BAL ﬂuid Neg R. microsporus culture
14 (L) 76 M Trauma Skin NA Biopsy Hyphae Mucor circinelloides culture
15 (L) 60 M Trauma Skin NA Biopsy Hyphae M. circinelloides culture
16 (L) 3 F ALL Disseminated Disseminated Vitreous humor Hyphae Lichtheimia sp. PCR
aALL, acute lymphoblastic leukemia; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; BAL, bronchoalveolar lavage; BDG,
(1,3)--D-glucan; CML, chronic myelogenous leukemia; Cq, quantiﬁcation cycle; DE, direct examination; EORTC, European Organization for Research and Treatment of
Cancer; F, female; GM, galactomannan; GVHD, graft-versus-host disease; ISA, isavuconazole; L-AMB, liposomal amphotericin B; L, Lille, France; M, male; MM,
mucormycosis; MS-DS, mass spectrometry method for detection of a serum disaccharide; NA, not available; Neg, negative; NS, not speciﬁed; P, Paris, France; POSA,
posaconazole. Bold characters correspond to positive values.
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their clearance, explaining their longer persistence than mannans (37, 38). Despite
considerable efforts to solve the problems of DNA extraction and standardization, the
lack of knowledge regarding the relationship between clinical outcome and Candida
PCR results has prevented clinical recommendations (39). Recent progress has been
made by the association of PCR with magnetic resonance detection in the T2MR
system, leading to good speciﬁcity and increased sensitivity with regard to blood
cultures for IC (25, 40). For MM and in the absence of other biomarkers, qPCR represents
signiﬁcant progress, as demonstrated by a large collaborative study showing its ability
to conﬁrm the diagnosis. Furthermore, the survival rate was signiﬁcantly higher in
patients with an initially positive PCR result that became negative after treatment
initiation than in patients whose PCR result remained positive (41). In our study,
Mucorales qPCR and MS-DS were complementary since all serum samples were positive
by at least one test. Although the signiﬁcance of DS persistence should be compared
to a positive PCR result, these results emphasize the beneﬁt of MS-DS in patient care,
principally due to the combination of biomarkers whose kinetics of synthesis and
release differ during the pathogenic processes. The panfungal characteristics of MS-DS
adapted to the broad diversity of emerging fungal pathogens presents some advan-
tages for ﬁrst-line screening. This simple, robust physicochemically based technology is
easily implementable in the majority of clinical mycology laboratories now equipped
TABLE 5 (Continued)
MM level of
certainty, EORTC Treatment Outcome
Delay vs time of mycological
evidence (days)
Cq value by PCR
for Mucorales
BDG concn
(pg/ml)
GM index
in serum
MS-DS
index
Probable L-AMB Death 15 Neg NA 0.5 3,333
0 Neg NA 0.5 123
7 Neg NA 0.5 278
Proven L-AMB Death 3 40 NA 0.5 37
Proven L-AMB Alive 45 Neg NA 0.5 3,333
51 Neg NA 0.5 3,333
Proven No Death 18 Neg NA 0.5 213
14 40 NA 0.5 122
7 37 NA 0.5 139
Possible L-AMB Death 0 31 NA 0.5 213
Possible L-AMB Alive 30 39 NA 0.5 100
Proven L-AMB Death 45 39 NA 0.5 123
Proven L-AMB Death 28 Neg NA 0.5 333
21 Neg NA 0.5 66
15 Neg NA 0.5 300
7 Neg NA 0.5 149
0 35 NA 0.5 222
12 31 NA 0.5 417
19 35 NA 0.5 1,000
21 39 NA 0.5 1,400
30 Neg NA 0.5 2,500
34 Neg NA 0.5 1,667
41 Neg NA 0.5 2,000
53 Neg NA 0.5 2,000
63 Neg NA 0.5 2,500
Proven No Death 4 35 0 0.07 132
Possible NS Alive 2 Neg 31 NA 132
5 37 18 NA 159
Proven Surgery, hyperbaric oxygen Death 9 33 42 0.15 300
6 34 46 NA 2,000
Proven L-AMB, surgery Alive 24 Neg 21 NA 1,429
Probable No Death 6 35 18 0.06 455
0 35 0 0.04 400
Proven Switch from POSA to L-AMB,
surgery, hyperbaric oxygen
Alive 16 Neg 39 NA 3,333
Proven L-AMB, surgery Alive 5 Neg 106 0.06 3,333
Proven ISA/L-AMB Alive 1 Neg 18 0.05 333
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with MALDI-TOF MS and can be adapted to single tests or a large series (42). However,
as the present collaborative study was retrospective, its promising results have to be
conﬁrmed through a prospective study. More generally, this method, which allows the
early identiﬁcation and quantiﬁcation of fungal glycans, is in its infancy, and studies are
in progress to explore its potential. In parallel, studies concerning the contribution of
MS-DS complemented with currently recommended tests are exploring the possibility
of improving antifungal stewardship based on a better knowledge of the diagnostic
and prognostic signiﬁcance of glycobiomarkers.
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